Literature DB >> 28245992

Overt and Subclinical Baroreflex Dysfunction After Bilateral Carotid Body Tumor Resection: Pathophysiology, Diagnosis, and Implications for Management.

Michael G Z Ghali1, Visish M Srinivasan2, Ehab Hanna3, Franco DeMonte4.   

Abstract

BACKGROUND: Carotid body paragangliomas are rare, usually benign, tumors arising from glomus cells of the carotid body. Bilateral involvement is present in ∼5% of sporadic cases and up to one third of familial cases. In most patients undergoing bilateral resection of carotid body tumors, a condition known as baroreflex failure syndrome (BFS) develops after resection of the second tumor characterized by headache, anxiety, emotional lability, orthostatic lightheadedness, hypertension, and tachycardia. This condition is believed to result from damage to the carotid baroreceptor apparatus. Patients without overt cardiovascular abnormalities may have subclinical baroreceptor dysfunction evident only on specific testing, measuring heart rate and sympathetic nerve responses to baroloading (e.g., phenylephrine) and barounloading (e.g., Valsalva maneuver). Given the high incidence of BFS in patients undergoing bilateral resection of carotid body tumors, it is suggested that operation is limited to unilateral resection of the dominant/symptomatic lesion and nonsurgical intervention (i.e., embolization, radiotherapy) on the contralateral side. Alternatively, refinement of surgical technique to prevent injury to elements of the baroreceptor apparatus may prevent this complication of bilateral tumor resection. METHODS AND
RESULTS: We present a case of a 16-year-old girl with bilateral jugular vagale and carotid body tumors who developed hypertension after surgical resection of her left jugular vagale tumor and worsening of hypertension concurrent with progression, requiring intensity-modulated radiation therapy and a resection for significant progression of her left jugular vagale tumor. Additional case studies and series of bilateral carotid body tumors and BFS were identified through a comprehensive literature search in the PubMed database.
CONCLUSIONS: Our case shows the generalizability of BFS to patients with tumors involving the vagal baroafferent fibers.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Baroreflex dysfunction; Baroreflex failure syndrome; Carotid body tumors; Paraganglioma

Mesh:

Year:  2017        PMID: 28245992     DOI: 10.1016/j.wneu.2017.02.073

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Blood Pressure Management in Afferent Baroreflex Failure: JACC Review Topic of the Week.

Authors:  Italo Biaggioni; Cyndya A Shibao; André Diedrich; James A S Muldowney; Cheryl L Laffer; Jens Jordan
Journal:  J Am Coll Cardiol       Date:  2019-12-10       Impact factor: 24.094

2.  Diagnosis and treatment of carotid body tumors.

Authors:  Junjie Liu; Hong Mu; Weidong Zhang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  A rare cause of arterial hypertension in a child with developmental delay: Answers.

Authors:  Cemile Pehlivanoglu; Hulya Maras Genc; Sevinc Kalın
Journal:  Pediatr Nephrol       Date:  2021-10-19       Impact factor: 3.714

4.  Carotid Body Tumor Microenvironment.

Authors:  Jean-Paul Bryant; Shelly Wang; Toba Niazi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Prevalence of orthostatic hypertension and its association with cerebrovascular diagnoses in patients with suspected TIA and minor stroke.

Authors:  Farzaneh Barzkar; Phyo K Myint; Chun Shing Kwok; Anthony Kneale Metcalf; John F Potter; Hamid Reza Baradaran
Journal:  BMC Cardiovasc Disord       Date:  2022-04-09       Impact factor: 2.298

6.  Operative management of symptomatic, metachronous carotid body tumors involving the skull base and its neurological sequelae.

Authors:  Roberto G Aru; Rony K Aouad; Justin F Fraser; Amanda M Romesberg; Kevin W Hatton; Sam C Tyagi
Journal:  J Vasc Surg Cases Innov Tech       Date:  2021-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.